Cite
HARVARD Citation
Orliaguet, M. et al. (2020). Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms. EJHaem. 1 (1), pp. 350-352. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Orliaguet, M. et al. (2020). Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms. EJHaem. 1 (1), pp. 350-352. [Online].